Development of shellfish allergy after exposure to dual immune checkpoint blockade
Hepatocellular carcinoma (HCC) is a major health problem worldwide with limited systemic therapies available. Immunotherapy is a fast-moving field that is quickly evolving as a treatment for HCC with three recent clinical trials published treating HCC with immune checkpoint inhibitors with promising...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis
2018-01-01
|
| Series: | Hepatic Oncology |
| Subjects: | |
| Online Access: | https://www.futuremedicine.com/doi/10.2217/hep-2017-0021 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Hepatocellular carcinoma (HCC) is a major health problem worldwide with limited systemic therapies available. Immunotherapy is a fast-moving field that is quickly evolving as a treatment for HCC with three recent clinical trials published treating HCC with immune checkpoint inhibitors with promising results. Checkpoint inhibition may lead to a unique adverse event profile with the potential to cause immune-related adverse events by unbalancing the immune system. Here, we report a case of a 61-year-old male with advanced HCC who developed a shellfish allergy after completing three cycles of combination of tremelimumab and durvalumab therapy. |
|---|---|
| ISSN: | 2045-0923 2045-0931 |